Abstract
Semaglutide is a glucagon-like peptide 1 agonist showing a high level of homology with human GLP-1. Its exceptionality lies in the fact that it is available both as a once weekly injection and a once daily pill.
Injectable semaglutide is, at present, the most potent non-insulin glucose-lowering agent with confirmed cardioprotective and renoprotective properties. The option of oral administration of semaglutide - a peptide - is one of the most significant innovations in diabetes care in last couple of years.
Oral semaglutide is the most potent oral glucose-lowering agent with an excellent effect not only on glucose control; its use is also associated with decrease of body weight, improvement of circulating lipids, and positive influence on other cardiovascular risk factors. In this review, we focus on oral semaglutide and its influence on the cardiovascular risk and on the risk factors of atherosclerosis and discuss further perspectives of its use in the prevention and therapy of cardiovascular complications of diabetes.